Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | -65.98%6.17M | -26.62%1.57M | -71.25%1.34M | -62.89%1.73M | -77.09%1.53M | -53.51%18.14M | -65.65%2.15M | -21.74%4.66M | -67.34%4.65M | -46.85%6.69M |
Operating revenue | -65.98%6.17M | -26.62%1.57M | -71.25%1.34M | -62.89%1.73M | -77.09%1.53M | -53.51%18.14M | -65.65%2.15M | -21.74%4.66M | -67.34%4.65M | -46.85%6.69M |
Cost of revenue | ||||||||||
Gross profit | ||||||||||
Operating expense | -20.83%76.15M | -40.34%13.52M | -27.68%18.81M | -2.42%23.1M | -13.06%20.72M | -5.93%96.18M | -16.67%22.67M | 10.46%26.01M | -15.88%23.67M | 2.03%23.83M |
Selling and administrative expenses | -1.63%22.11M | -7.63%4.71M | -22.34%4.54M | 26.20%7.55M | -4.32%5.31M | 26.02%22.48M | 20.05%5.1M | 67.25%5.84M | 15.00%5.98M | 13.49%5.55M |
-General and administrative expense | -1.63%22.11M | -7.63%4.71M | -22.34%4.54M | 26.20%7.55M | -4.32%5.31M | 26.02%22.48M | 20.05%5.1M | 67.25%5.84M | 15.00%5.98M | 13.49%5.55M |
Research and development costs | -26.68%54.04M | -49.84%8.81M | -29.23%14.27M | -12.10%15.55M | -15.72%15.4M | -12.69%73.7M | -23.47%17.56M | 0.57%20.17M | -22.88%17.69M | -1.01%18.28M |
Operating profit | 10.33%-69.97M | 41.77%-11.95M | 18.18%-17.47M | -12.36%-21.37M | -11.92%-19.18M | -23.43%-78.03M | 2.07%-20.52M | -21.35%-21.35M | -36.83%-19.02M | -59.10%-17.14M |
Net non-operating interest income expense | 23.31%6.45M | 0.91%1.43M | 18.65%1.72M | 39.15%1.8M | 40.28%1.5M | 1,022.10%5.23M | 124.13%1.42M | 446.42%1.45M | 1,600.00%1.29M | 408.36%1.07M |
Non-operating interest income | 15.77%6.59M | -0.07%1.46M | 16.93%1.75M | 25.19%1.83M | 21.85%1.55M | 159.49%5.69M | 55.36%1.47M | 115.27%1.49M | 268.94%1.46M | 697.48%1.27M |
Non-operating interest expense | -70.15%137K | -31.82%30K | -36.96%29K | -80.12%34K | -77.78%44K | -73.41%459K | -85.76%44K | -89.28%46K | -64.52%171K | -60.87%198K |
Other net income (expense) | -14,431.82%-6.39M | -847.42%-2.02M | -1,891.96%-3.96M | -134.38%-219K | 28.25%-193K | 98.05%-44K | 86.79%-213K | 15.68%-199K | 410.73%637K | -33.83%-269K |
Gain on sale of security | -296.00%-49K | -335.71%-33K | -16.67%5K | -900.00%-8K | -425.00%-13K | 213.64%25K | 450.00%14K | 128.57%6K | -66.67%1K | --4K |
Special income (charges) | -9,095.65%-6.35M | -774.45%-1.99M | -1,836.10%-3.97M | -133.18%-211K | 34.07%-180K | 96.91%-69K | 85.89%-227K | 4.65%-205K | 405.77%636K | -35.82%-273K |
-Less:Restructuring and merger&acquisition | 9,095.65%6.35M | 774.45%1.99M | 1,836.10%3.97M | 133.18%211K | -34.07%180K | -96.91%69K | -85.89%227K | -4.65%205K | -405.77%-636K | 35.82%273K |
Income before tax | 4.02%-69.92M | 35.11%-12.53M | 1.92%-19.72M | -15.81%-19.8M | -9.40%-17.88M | -12.05%-72.85M | 11.95%-19.31M | -14.44%-20.1M | -20.45%-17.09M | -44.32%-16.34M |
Income tax | 0 | 0 | ||||||||
Net income | 4.02%-69.92M | 35.11%-12.53M | 1.92%-19.72M | -15.81%-19.8M | -9.40%-17.88M | -4.89%-72.85M | 11.95%-19.31M | -14.44%-20.1M | -20.45%-17.09M | -3.64%-16.34M |
Net income continuous Operations | 4.02%-69.92M | 35.11%-12.53M | 1.92%-19.72M | -15.81%-19.8M | -9.40%-17.88M | -4.89%-72.85M | 11.95%-19.31M | -14.44%-20.1M | -20.45%-17.09M | -3.64%-16.34M |
Minority interest income | ||||||||||
Net income attributable to the parent company | 4.02%-69.92M | 35.11%-12.53M | 1.92%-19.72M | -15.81%-19.8M | -9.40%-17.88M | -4.89%-72.85M | 11.95%-19.31M | -14.44%-20.1M | -20.45%-17.09M | -3.64%-16.34M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | 4.02%-69.92M | 35.11%-12.53M | 1.92%-19.72M | -15.81%-19.8M | -9.40%-17.88M | -4.89%-72.85M | 11.95%-19.31M | -14.44%-20.1M | -20.45%-17.09M | -3.64%-16.34M |
Basic earnings per share | 13.64%-0.38 | 41.67%-0.07 | 16.67%-0.1 | -10.00%-0.11 | 0.00%-0.1 | 4.35%-0.44 | 14.29%-0.12 | 0.00%-0.12 | 0.00%-0.1 | 9.09%-0.1 |
Diluted earnings per share | 13.64%-0.38 | 41.67%-0.07 | 16.67%-0.1 | -10.00%-0.11 | 0.00%-0.1 | 4.35%-0.44 | 14.29%-0.12 | 0.00%-0.12 | 0.00%-0.1 | 9.09%-0.1 |
Dividend per share | ||||||||||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | -- | -- | -- | -- | -- |